Karyopharm, Menarini receive full Marketing Authorization for Nexpovio

Karyopharm Therapeutics and the Menarini Group announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted full Marketing Authorization for Nexpovio in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. With this approval extending Nexpovio’s indication in Great Britain, the conditional marketing authorization is now converted to full approval, the company said in a statement. Stemline Therapeutics, a wholly owned subsidiary of the Menarini Group, will be responsible for all commercialization activities in the U.K.